Anfield Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,977
| Closed | -$1.2M | – | 487 |
|
|
2024
Q4 | $1.2M | Hold |
2,977
| – | – | 0.44% | 40 |
|
|
2024
Q3 | $1.38M | Buy |
+2,977
| New | +$1.38M | 0.53% | 37 |
|
|
2024
Q2 | – | Sell |
-2,576
| Closed | -$1.08M | – | 535 |
|
|
2024
Q1 | $1.08M | Buy |
+2,576
| New | +$1.08M | 0.52% | 49 |
|
|
2023
Q3 | – | Sell |
-2,604
| Closed | -$916K | – | 87 |
|
|
2023
Q2 | $916K | Buy |
+2,604
| New | +$916K | 0.4% | 50 |
|
|
2023
Q1 | – | Sell |
-532
| Closed | -$154K | – | 92 |
|
|
2022
Q4 | $154K | Sell |
532
-711
| -57% | -$205K | 0.08% | 69 |
|
|
2022
Q3 | $360K | Buy |
1,243
+43
| +4% | +$12.5K | 0.17% | 61 |
|
|
2022
Q2 | $338K | Buy |
1,200
+172
| +17% | +$48.4K | 0.15% | 62 |
|
|
2022
Q1 | $268K | Buy |
1,028
+588
| +134% | +$153K | 0.1% | 68 |
|
|
2021
Q4 | $97K | Buy |
440
+400
| +1,000% | +$88.2K | 0.03% | 80 |
|
|
2021
Q3 | $7K | Buy |
+40
| New | +$7K | ﹤0.01% | 96 |
|